Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. She is currently on leave.
More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero � all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

The Future of Pharma Profits

By Megan McArdle
Sep 25 2009, 4:06 PM ET Comment

When I was talking about pharma's role in innovation, a lot of people confused this with being pro-pharma. The implication was that I should be in favor of anything that's good for Big CDrugs.  This is sort of like thinking that because I like watching Derek Jeter play baseball, I would also enjoy watching him stab a puppy to death.

Hence I am not happy, but outraged, by this:



Time for a brief comment on health care reform, now that Sen. Baucus has presented a bill to the Finance Committee (which, to be sure, I believe has already attracted over 500 proposed amendments). As is well known, the largest drug industry trade group, PhRMA, signed on to the whole idea of a large reform effort early, in exchange for a seat at the table (and a chance to make things go favorably). How's that working out so far?

As Steve Usdin at Biocentury writes, the answer is "fairly blatantly":

The parochial value of PhRMA's controversial decision to cut a deal with the Senate Finance Committee and the White House became clear last week as details of the committee's healthcare reform bill emerged that favor big pharma companies over their biotech siblings. The bill also pounds the medical device industry and slams laboratory service providers, sectors that didn't agree on "voluntary" contributions to healthcare expansion. . .

. . .A 233-page summary of the America's Healthy Future Act released by Finance Committee Chairman Max Baucus (D-Mont.) includes most of PhRMA's healthcare reform wish list and has only one major provision pharma companies hope to kill: a commission with powers to constrain Medicare spending.

The tax put on medical devices by this bill has already been noted widely in the press, and I see that Sen. Kerry is already objecting to that provision - naturally enough, since Massachusetts has some big players in that area. The Senators from Guidant and Medtronics (also known as Indiana and Minnesota) are speaking up as well. The trade association for that industry (AdvaMed) apparently couldn't come to terms with Washington, so this tax is their reward - which, in a nutshell, is the sort of thing that keeps gradually turning me into a libertarian.

Profits are good when they result from providing a service people want.  When they are the result of capturing the government by cutting special deals, they're immoral and inefficient.  And this is just the beginning . . .

Presented by

More at The Atlantic

Watch and Buy: Kickstarter Is the Hipster Home Shopping Network Kickstarter Is the Hipster Home Shopping Network
How One Mother's Story Helped Change Obama's Gay Marriage Stance How A Mother's Story Changed Obama's Gay-Marriage Stance
The '7 Dirty Words' Turn 40, but They're Still Dirty The '7 Dirty Words' Turn 40
Meet the 'Fly Boys' of Memphis, the Future of American Education Meet the 'Fly Boys' of Memphis, the Future of Education
The Right-Wing Ideologue's Guide to Obama's Teenage Pot Smoking How to Spin Obama's Teenage Pot Smoking

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
View All Correspondents

The Biggest Story in Photos

Where in the World? Part 3: A Google Earth Puzzle

May 25, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why You Can’t Get a Taxi

And how an upstart company may change that

Europe’s Real Crisis

The Continent’s problems are as much demographic as financial. They won’t go away soon.

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…